Ten years ago, Victoria Hale wrote a manifesto targeting five diseases in need of drug development and turned it into a business plan for the first pharmaceutical not-for-profit in the United States. Today, her organization, the Institute for OneWorld Health, is on the verge of proving that its no-profit/no-loss model can work. Its first drug, paromomycin — a treatment for visceral leishmaniasis, an illness spread by sand flies that mostly afflicts the poorest of the poor — is months from completing its final stage of clinical trials. Up next: malaria. Backed by a $42.6 million grant from the Gates Foundation, OneWorld Health aims to create and market semisynthetic artemisinin, a key malaria-fighting ingredient that’s in short supply.
collections
NewsletterAdvertiseCurrent IssueTech Forecast
What’s next for hardware, software, and services
Most Innovative Companies
Our annual guide to the businesses that matter the most
Most Creative People
Leaders who are shaping the future of business in creative ways
World Changing Ideas
New workplaces, new food sources, new medicine--even an entirely new economic system
Innovation By Design
Celebrating the best ideas in business